The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Marking the third alliance between the companies, AstraZeneca and Astex Therapeutics (primarily developing cancer drugs) have entered into an agreement to develop small-molecule inhibitors of protein kinase B (PKB).

Astex gets £2.75mm ($5mm) up front, research funding, and development, regulatory, and sales milestones of up to £150mm. It could also receive double-digit royalties on sales of any approved products. AZ gets worldwide development and commercialization rights to PKB inhibitors discovered under Astex's ongoing collaboration with the Institute of Cancer Research and Cancer Research Technology; Astex retains US co-promotion rights. The candidates target PKB, a protein that is activated in tumors following the disruption of the tumor suppressor PTEN. PKB's up-regulation is associated with resistance to many chemotherapeutics, especially EGFR kinase inhibitors (such as AZ's Iressa), and for this reason has potential in combination therapies for different cancers. AZ and Astex's previous deals involved cytochrome P450 interactions (2001) and the discovery of drugs for Alzheimer's disease that inhibit beta-secretase (2003).


Update 01/2010

Astex has received a "significant" milestone payment from AstraZeneca after AZ selected a drug candidate for clinical development.


+ Show All | – Hide All

Financials


Click a figure for comparable deals.

Overview
Potential Deal Value $268.00mm
Upfront Total $5.00mm
Total Milestones (pre- and post-sales) $263.00mm
Transactions 1 of 2 (07/2005)
Funding Stage Upfront
Upfront (Cash) $5.00mm
Upfront (Total) $5.00mm
Transactions 2 of 2
Funding Stage MS Pre & Post Tot.
MS Pre & Post Tot. (Cash) $263.00mm
MS Pre & Post Tot. (Total) $263.00mm

Deal Information


Click a keyword for comparable deals.

Deal Industry Biotechnology
Pharmaceuticals
Deal Status Final
Deal Type Alliance
R+D and Marketing-Licensing
Co-Promotion
Includes Royalty or Profit Split Information
Latest Phase at Time of Deal Research
Preclinical

Product Information


Click a keyword for comparable deals.

Product 1 of 1
Product Type Pharmaceutical
Mechanism of Action Protein kinase B inhibitor
Highest Phase at Time of Deal Research
Preclinical
Product Therapeutic Area(s) of Focus Cancer
Licenser Name Astex Therapeutics Ltd.
Clinical Developer AstraZeneca PLC
Licensee Name AstraZeneca PLC
Carveouts for AstraZeneca PLC
Territories Licensed Worldwide (All)

Company Information


Click a keyword for comparable companies.

AstraZeneca PLC www.astrazeneca.com | Ticker: AZN
View Company Profile | View Company Deals
Company Location Worldwide
Europe
Western Europe
UK
Industry Pharmaceuticals
Description Big Pharma
Ownership Public
Therapeutic Area(s) of Focus Cancer
Cardiovascular
Gastrointestinal
Infectious & Viral Diseases
Inflammation
Neurology, Nervous System
Respiratory, Pulmonary

Otsuka Holdings Co. Ltd. www.otsuka.com
View Company Profile | View Company Deals
Company Location Worldwide
Asia
Pacific Rim
Japan
Industry Diversified
In Vitro Diagnostics
Pharmaceuticals
Nutraceuticals
OTC, Consumer
Description Top Japanese Pharma
Ownership Public
Therapeutic Area(s) of Focus Non-Specific
Revenue $15,413.80mm

Otsuka Pharmaceutical Co. Ltd.
a division of Otsuka Holdings Co. Ltd.
www.otsuka.co.jp/en/
View Company Profile | View Company Deals
Company Location Worldwide
Asia
Pacific Rim
Japan
Industry In Vitro Diagnostics
Chemistry, Immunoassay
Medical Devices
Pharmaceuticals
Nutraceuticals
OTC, Consumer
Ownership Private
Therapeutic Area(s) of Focus Non-Specific
Revenue $6,400.00mm

Astex Pharmaceuticals Inc.
a division of Otsuka Holdings Co. Ltd.
astx.com
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
CA
Industry Biotechnology
Drug Discovery Tools
Bioinformatics
Molecular Diversity
Pharmaceuticals
Ownership Private
Therapeutic Area(s) of Focus Cancer
Alias(es) SuperGen Inc.

Astex Therapeutics Ltd.
a division of Otsuka Holdings Co. Ltd.
www.astex-therapeutics.com
View Company Profile | View Company Deals
Company Location Worldwide
Europe
Western Europe
UK
Industry Biotechnology
Drug Discovery Tools
Pharmaceuticals
Status Absorbed
Ownership Private
Therapeutic Area(s) of Focus Cancer
Infectious & Viral Diseases
Alias(es) Astex Technology Ltd.